Therapy monitoring and follow-up of lung cancer are key to individualized patient treatment. Monitoring the tumor’s response allows a timely adaptation to the selected therapy. This is important when several therapeutic options are available, as is the case with lung cancer.
After completion of the therapy, a systematic follow-up for the early detection of lung cancer relapse should always be part of the patient’s workup and is described in the corresponding guidelines.
Computed Tomography & syngo.via
- through functional examinations like tissue perfusion or iodine quantification SOMATOM CT systems enable an earlier assessment of tumor’s response in the lung or disease progression
- syngo.via-based reading applications permit a standardized and efficient image analysis
- longitudinal studies of the same patient are automatically registered, the trending of lesion size change is automatically visualized
- structured reporting allows efficient communication across departments and disciplines
Positron Emission Tomography
- early predictor of response
- advanced system calibration of Biograph PET/CT systems helps ensure consistent quantitative accuracy across multiple time points
- Small, 4 mm LSO crystals provide high sensitivity in detecting local and distant recurrences of lung carcinoma
- syngo.via with EQ•PET helps reduce technology-induced variations and inter-reader variability by normalizing PET SUV values between different scanners and reconstruction methods
- Continuous bed motion, made possible by FlowMotion™ technology supports precise disease characterization in therapy monitoring of lung cancer
- comprehensive menu of oncology tests, e.g. general and specific tests to assess side-effects in the patient or tumor markers such as carcinoembryonic antigen (CEA)